摘要: Summary points A wide variety of drugs is available for treating Parkinson9s disease, including anticholinergics, amantadine levodopa, dopamine agonists, and selegeline In younger patients ( 70) levodopa should be started as soon symptom relief required. Between these ages there no consensus, but at present most such probably given controlled release before a agonist added Fluctuations can often alleviated by giving preparations small doses frequent intervals, adding selegiline or long acting oral agonist, subcutaneous apomorphine Dyskinesia peak dose, diphasic, “off period.” The diphasic form hardest to alleviate Psychiatric side effects initially managed changing the antiparkinsonian treatment resorting antipsychotic
sci-hub.st 参考文章(25)
J. W. Roberts, G. Cora-Locatelli, D. Bravi, M. A. Amantea, M. M. Mouradian, T. N. Chase, Catechol‐O‐methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients Neurology. ,vol. 43, pp. 2685- 2685 ,(1993) , 10.1212/WNL.43.12.2685
C. Siktröm, L. Beckmana, G. Dahlén, O. Johnson, Transferrin C subtypes and myocardial infarction. Human Heredity. ,vol. 43, pp. 21- 24 ,(1993) , 10.1159/000154108
V. Kostic, S. Przedborski, E. Flaster, N. Sternic, Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology. ,vol. 41, pp. 202- 202 ,(1991) , 10.1212/WNL.41.2_PART_1.202
U. K. Rinne, Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: A 5‐year follow‐up Neurology. ,vol. 37, pp. 826- 826 ,(1987) , 10.1212/WNL.37.5.826
B. Bergamasco, P. Benna, L. Scarzella, Long‐term bromocriptine treatment of de novo patients with Parkinson's disease. A seven‐year follow‐up Acta Neurologica Scandinavica. ,vol. 81, pp. 383- 387 ,(2009) , 10.1111/J.1600-0404.1990.TB00980.X
Y de Smet, M Ruberg, M Serdaru, B Dubois, F Lhermitte, Y Agid, Confusion, dementia and anticholinergics in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. ,vol. 45, pp. 1161- 1164 ,(1982) , 10.1136/JNNP.45.12.1161
D. E. Riley, A. E. Lang, The spectrum of levodopa‐related fluctuations in Parkinson's disease Neurology. ,vol. 43, pp. 1459- 1459 ,(1993) , 10.1212/WNL.43.8.1459
M. Maral Mouradian, Isabella J. E. Heuser, Fabio Baronti, Thomas N. Chase, Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Annals of Neurology. ,vol. 27, pp. 18- 23 ,(1990) , 10.1002/ANA.410270105
J. P. Hammerstad, A. Gordin, J. G. Nutt, W. R. Woodward, R. M. Beckner, C. K. Stone, K. Berggren, J. H. Carter, S. T. Gancher, Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients Neurology. ,vol. 44, pp. 913- 913 ,(1994) , 10.1212/WNL.44.5.913
M A Hely, J G Morris, D Rail, W G Reid, D J O'Sullivan, P M Williamson, S Genge, G A Broe, The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years. Journal of Neurology, Neurosurgery, and Psychiatry. ,vol. 52, pp. 324- 328 ,(1989) , 10.1136/JNNP.52.3.324